AAPL   390.28 (+1.72%)
MSFT   212.01 (-0.78%)
FB   244.17 (-0.37%)
NVDA   416.90 (-0.54%)
GE   6.81 (+1.64%)
TSLA   1,604.47 (+3.87%)
ACB   12.36 (+2.83%)
NFLX   550.57 (+0.34%)
BAC   24.37 (+1.46%)
AAPL   390.28 (+1.72%)
MSFT   212.01 (-0.78%)
FB   244.17 (-0.37%)
NVDA   416.90 (-0.54%)
GE   6.81 (+1.64%)
TSLA   1,604.47 (+3.87%)
ACB   12.36 (+2.83%)
NFLX   550.57 (+0.34%)
BAC   24.37 (+1.46%)
AAPL   390.28 (+1.72%)
MSFT   212.01 (-0.78%)
FB   244.17 (-0.37%)
NVDA   416.90 (-0.54%)
GE   6.81 (+1.64%)
TSLA   1,604.47 (+3.87%)
ACB   12.36 (+2.83%)
NFLX   550.57 (+0.34%)
BAC   24.37 (+1.46%)
AAPL   390.28 (+1.72%)
MSFT   212.01 (-0.78%)
FB   244.17 (-0.37%)
NVDA   416.90 (-0.54%)
GE   6.81 (+1.64%)
TSLA   1,604.47 (+3.87%)
ACB   12.36 (+2.83%)
NFLX   550.57 (+0.34%)
BAC   24.37 (+1.46%)
Log in

NASDAQ:AZRXAzurRx BioPharma Stock Price, Forecast & News

$0.84
-0.01 (-1.18 %)
(As of 07/13/2020 03:06 PM ET)
Add
Compare
Today's Range
$0.83
Now: $0.84
$0.86
50-Day Range
$0.80
MA: $0.90
$1.02
52-Week Range
$0.37
Now: $0.84
$1.94
Volume2,300 shs
Average Volume128,031 shs
Market Capitalization$23.69 million
P/E RatioN/A
Dividend YieldN/A
Beta2.03
AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.
Read More
AzurRx BioPharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AZRX
CUSIPN/A
Phone646-699-7855

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.17 per share

Profitability

Net Income$-15,180,000.00

Miscellaneous

Employees12
Market Cap$23.69 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive AZRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter.

AzurRx BioPharma (NASDAQ:AZRX) Frequently Asked Questions

How has AzurRx BioPharma's stock been impacted by COVID-19 (Coronavirus)?

AzurRx BioPharma's stock was trading at $0.6150 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AZRX stock has increased by 36.6% and is now trading at $0.84. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AzurRx BioPharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AzurRx BioPharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AzurRx BioPharma.

When is AzurRx BioPharma's next earnings date?

AzurRx BioPharma is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for AzurRx BioPharma.

How were AzurRx BioPharma's earnings last quarter?

AzurRx BioPharma Inc (NASDAQ:AZRX) released its quarterly earnings results on Friday, May, 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.09. View AzurRx BioPharma's earnings history.

What price target have analysts set for AZRX?

3 equities research analysts have issued 1-year price targets for AzurRx BioPharma's shares. Their forecasts range from $2.00 to $3.00. On average, they expect AzurRx BioPharma's share price to reach $2.50 in the next year. This suggests a possible upside of 197.6% from the stock's current price. View analysts' price targets for AzurRx BioPharma.

Has AzurRx BioPharma been receiving favorable news coverage?

News articles about AZRX stock have been trending very negative recently, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AzurRx BioPharma earned a daily sentiment score of -3.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about AzurRx BioPharma.

Are investors shorting AzurRx BioPharma?

AzurRx BioPharma saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 145,500 shares, an increase of 95.6% from the May 31st total of 74,400 shares. Based on an average trading volume of 305,500 shares, the short-interest ratio is presently 0.5 days. Approximately 0.6% of the shares of the stock are short sold. View AzurRx BioPharma's Current Options Chain.

Who are some of AzurRx BioPharma's key competitors?

What other stocks do shareholders of AzurRx BioPharma own?

Who are AzurRx BioPharma's key executives?

AzurRx BioPharma's management team includes the following people:
  • Mr. Johan M. Spoor, Pres, CEO & Director (Age 47)
  • Mr. Maged S. Shenouda M.B.A., R.Ph., R.Ph, MBA, CFO & Director (Age 55)
  • Mr. Daniel Dupret, Chief Scientific Officer (Age 63)
  • Dr. Mathieu Schué Ph.D., Head of Laboratory
  • Dr. James E. Pennington, Chief Medical Officer (Age 76)

When did AzurRx BioPharma IPO?

(AZRX) raised $15 million in an initial public offering (IPO) on Friday, September 9th 2016. The company issued 2,100,000 shares at a price of $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities acted as the underwriters for the IPO.

What is AzurRx BioPharma's stock symbol?

AzurRx BioPharma trades on the NASDAQ under the ticker symbol "AZRX."

How do I buy shares of AzurRx BioPharma?

Shares of AZRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AzurRx BioPharma's stock price today?

One share of AZRX stock can currently be purchased for approximately $0.84.

How big of a company is AzurRx BioPharma?

AzurRx BioPharma has a market capitalization of $23.69 million. AzurRx BioPharma employs 12 workers across the globe.

What is AzurRx BioPharma's official website?

The official website for AzurRx BioPharma is www.azurrx.com.

How can I contact AzurRx BioPharma?

AzurRx BioPharma's mailing address is 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226. The company can be reached via phone at 646-699-7855 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.